August 21, 1996
Amsterdam, The Netherlands
This supplement, "Managing the Risk of Venous Thromboembolism in Orthopedics," focuses on the serious complication of total hip or knee arthroplasty - venous thromboembolism. Mechanical and pharmacological interventions are widely used to prevent this complication. Low-molecular-weight heparin is proving to be one of the more effective and most easily managed pharmacologic treatments and this issue focuses on its use.
Numerous clinical trials have provided evidence that low-molecular-weight heparin is a useful tool in managing the risk of thrombosis in the perioperative period and in the postoperative period. The participants, recognized experts in this field, of this symposium presented useful information on the risk assessment of patients in both periods and new information on the pharmacological agents that most benefit the prevention of venous thromboembolism.
I hope our readers find this information useful in the management of preventing thromboembolism in their orthopedic patients.
Robert D'Ambrosia, MD
Robert H. Fitzgerald Jr, MD
Dr Fitzgerald is from the Department of Orthopedic Surgery at the University of Pennsylvania School of Medicine in Philadelphia.
Sylvia Haas, MD
Dr Haas is from the Institute Experimental Surgery at Technical University of Munich in Munich, Germany.
Guy D. Paiement, MD
Dr Paiement is from the University of California at San Francisco in San Francisco, Calif.
Michael R. Lassen, MD
Dr Lassen is from the Department of Orthopedics at Hillered Hospital in Hi Herod, Denmark.
Paul E. Nilsson, MD
Dr Nilsson is from the Department of Diagnostic Radiology at Malmö University Hospital in Malrno, Sweden.
André Planes, MD
Dr Planes is from the Clinique Radio-Chururgicale du Mail in La Rochelle, France.
A.G.G. Turple, MD
Dr Turpie is from the Department of Medicine at McMaster University, Hamilton General Hospital in Hamilton, Ontario, Canada.